Denmark · Delayed Price · Currency is DKK ChemoMetec Statistics
Total Valuation
ChemoMetec has a market cap or net worth of DKK 12.40 billion. The enterprise value is 12.06 billion.
| Market Cap | 12.40B |
| Enterprise Value | 12.06B |
Important Dates
The next estimated earnings date is Wednesday, February 4, 2026.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Oct 10, 2025 |
Share Statistics
ChemoMetec has 17.40 million shares outstanding.
| Current Share Class | 17.40M |
| Shares Outstanding | 17.40M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 3.74% |
| Owned by Institutions (%) | 42.37% |
| Float | 16.75M |
Valuation Ratios
The trailing PE ratio is 66.53 and the forward PE ratio is 53.84. ChemoMetec's PEG ratio is 4.21.
| PE Ratio | 66.53 |
| Forward PE | 53.84 |
| PS Ratio | 25.02 |
| PB Ratio | 18.41 |
| P/TBV Ratio | 23.83 |
| P/FCF Ratio | 69.82 |
| P/OCF Ratio | 59.77 |
| PEG Ratio | 4.21 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 48.71, with an EV/FCF ratio of 67.93.
| EV / Earnings | 64.72 |
| EV / Sales | 24.34 |
| EV / EBITDA | 48.71 |
| EV / EBIT | 51.01 |
| EV / FCF | 67.93 |
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.70 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | 0.04 |
| Interest Coverage | 378.43 |
Financial Efficiency
Return on equity (ROE) is 30.10% and return on invested capital (ROIC) is 23.67%.
| Return on Equity (ROE) | 30.10% |
| Return on Assets (ROA) | 19.65% |
| Return on Invested Capital (ROIC) | 23.67% |
| Return on Capital Employed (ROCE) | 34.73% |
| Revenue Per Employee | 2.92M |
| Profits Per Employee | 1.10M |
| Employee Count | 170 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 0.26 |
Taxes
In the past 12 months, ChemoMetec has paid 53.61 million in taxes.
| Income Tax | 53.61M |
| Effective Tax Rate | 22.34% |
Stock Price Statistics
The stock price has increased by +82.77% in the last 52 weeks. The beta is 1.59, so ChemoMetec's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +82.77% |
| 50-Day Moving Average | 647.76 |
| 200-Day Moving Average | 552.74 |
| Relative Strength Index (RSI) | 56.33 |
| Average Volume (20 Days) | 53,711 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ChemoMetec had revenue of DKK 495.57 million and earned 186.41 million in profits. Earnings per share was 10.71.
| Revenue | 495.57M |
| Gross Profit | 465.51M |
| Operating Income | 236.52M |
| Pretax Income | 240.01M |
| Net Income | 186.41M |
| EBITDA | 247.68M |
| EBIT | 236.52M |
| Earnings Per Share (EPS) | 10.71 |
Balance Sheet
The company has 341.85 million in cash and 6.40 million in debt, giving a net cash position of 335.45 million or 19.28 per share.
| Cash & Cash Equivalents | 341.85M |
| Total Debt | 6.40M |
| Net Cash | 335.45M |
| Net Cash Per Share | 19.28 |
| Equity (Book Value) | 673.36M |
| Book Value Per Share | 38.69 |
| Working Capital | 396.17M |
Cash Flow
In the last 12 months, operating cash flow was 207.45 million and capital expenditures -29.87 million, giving a free cash flow of 177.58 million.
| Operating Cash Flow | 207.45M |
| Capital Expenditures | -29.87M |
| Free Cash Flow | 177.58M |
| FCF Per Share | 10.20 |
Margins
Gross margin is 93.93%, with operating and profit margins of 47.73% and 37.61%.
| Gross Margin | 93.93% |
| Operating Margin | 47.73% |
| Pretax Margin | 48.43% |
| Profit Margin | 37.61% |
| EBITDA Margin | 49.98% |
| EBIT Margin | 47.73% |
| FCF Margin | 35.83% |
Dividends & Yields
This stock pays an annual dividend of 7.00, which amounts to a dividend yield of 0.96%.
| Dividend Per Share | 7.00 |
| Dividend Yield | 0.96% |
| Dividend Growth (YoY) | 75.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 37.34% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.96% |
| Earnings Yield | 1.50% |
| FCF Yield | 1.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ChemoMetec has an Altman Z-Score of 34.64 and a Piotroski F-Score of 5.
| Altman Z-Score | 34.64 |
| Piotroski F-Score | 5 |